title: Ceftriaxone no longer predictably cures chancroid in Kenya.
abstract: Ceftriaxone in a dose of 250 mg given intramuscularly is currently recommended for the treatment of chancroid. Among 133 men in Nairobi, Kenya, with culture-proven chancroid, who were treated with ceftriaxone, treatment failed in 35%. Poor outcome was associated with human immunodeficiency virus type 1 seropositivity. Thus, treatment recommendations for chancroid should be reevaluated.
authors.affiliation: Department of Medicine, University of Manitoba, Winnipeg, Canada.
authors.forename: M
authors.initials: M
authors.lastname: Tyndall
authors.forename: M
authors.initials: M
authors.lastname: Malisa
authors.forename: F A
authors.initials: FA
authors.lastname: Plummer
authors.forename: J
authors.initials: J
authors.lastname: Ombetti
authors.forename: J O
authors.initials: JO
authors.lastname: Ndinya-Achola
authors.forename: A R
authors.initials: AR
authors.lastname: Ronald
mesh_terms: D000328:Adult; D002443:Ceftriaxone / Q000627:therapeutic use*; D002602:Chancroid / Q000150:complications / Q000188:drug therapy*; D005500:Follow-Up Studies; D006679:HIV Seropositivity / Q000150:complications*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007630:Kenya; D008297:Male; D016896:Treatment Outcome
chemical_list: D002443:Ceftriaxone